COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

11.90 -0.05 (-0.42%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2

...

27 28 29 30 31 32 33 34 Next >

Psychedelic Stock Gainers And Losers From March 2, 2022 ↗

March 02, 2022

GAINERS: Mindset Pharma (OTC:

Via Benzinga

Psychedelic Therapies Offer Hope For Mental Health ↗

March 02, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice....

Via Benzinga

Psychedelic Therapies Offer Hope for Mental Health

March 02, 2022

Via Investor Brand Network

Psychedelic Therapies Offer Hope for Mental Health

March 02, 2022

Via Investor Brand Network

Psychedelic Therapies Offer Hope for Mental Health

March 02, 2022

NetworkNewsWire Editorial Coverage New York, NY – March 2, 2022 – Neural plasticity is instrumental in brain health, and the importance of neuroplasticity can’t be overstated. Indeed, the inability of...

Via FinancialNewsMedia

Psychedelic Stock Gainers And Losers From March 1, 2022 ↗

March 01, 2022

GAINERS: Cybin (AMEX:

Via Benzinga

Psychedelic Stock Gainers And Losers From February 28, 2022 ↗

February 28, 2022

GAINERS: Wellbeing Digital (OTC:

Via Benzinga

Psychedelic & Marijuana Drug Stocks Continue To Decline ↗

February 27, 2022

This article updates the latest stock performances of the 13 clinical-stage companies with the largest market capitalizations which are tracked in the munKNEE Pure-Play Marijuana (4) and the munKNEE...

Via Talk Markets

Field Trip Health, Seelos Therapeutics Among Top Psychedelic Movers Of Today ↗

February 25, 2022

GAINERS: Field Trip Health (NASDAQ:

Via Benzinga

Psychedelic Stock Gainers And Losers From February 24, 2022 ↗

February 24, 2022

GAINERS: Seelos Therapeutics (NASDAQ:

Via Benzinga

COMPASS Pathways Posts Wider Net Loss In Q4, Gives Update On Psilocybin Research ↗

February 24, 2022

COMPASS Pathways plc (NASDAQ:CMPS) reported its fi...

Via Benzinga

Small Pharma, GH Research Among Top Psychedelic Movers Of Today ↗

February 23, 2022

GAINERS: Small Pharma (OTC:

Via Benzinga

Compass Pathways Earnings Preview ↗

February 23, 2022

Compass Pathways (NASDAQ:CMPS) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

Psychedelic Stock Gainers And Losers From February 22, 2022 ↗

February 22, 2022

GAINERS: LOSERS: Mindset Pharma (OTC:

Via Benzinga

Psychedelic & Marijuana Drug Stocks Continued To Decline Last Week ↗

February 21, 2022

An update on the stock performances of the 13 clinical-stage psychedelic and marijuana drug companies with the largest market capitalizations.tttttttttt

Via Talk Markets

Field Trip Health, Mind Medicine Among Top Psychedelic Movers Of Today ↗

February 18, 2022

GAINERS: Field Trip Health (NASDAQ:

Via Benzinga

Psychedelic Stock Gainers And Losers From February 17, 2022 ↗

February 17, 2022

GAINERS: Mindset Pharma (OTC:

Via Benzinga

Magic Mushroom's Active Compound Could Relieve Depression For Up To One Year, New Study Finds ↗

February 16, 2022

A new review study by Johns Hopkins University researchers is shedding light on the long-term effects of psilocybin in the treatment of maj...

Via Benzinga

Psychedelic Stock Gainers And Losers From February 15, 2022 ↗

February 15, 2022

GAINERS: Mind Medicine (NASDAQ:

Via Benzinga

Psychedelic Stock Gainers And Losers From February 14, 2022 ↗

February 14, 2022

GAINERS: Wellbeing Digital (OTC:

Via Benzinga

Psychedelic And Cannabis Drug Stocks Continue Advance ↗

February 13, 2022

This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses.

Via Talk Markets

Mind Medicine, Cybin Among Top Psychedelic Movers Of Today ↗

February 11, 2022

GAINERS: Revive Therapeutics (OTC: RVVTF) shares closed up 2.51% at $0.22 LOSERS: Mind Medicine (NASDAQ: MNMD) shares closed down 8.09% at $1.25 Cybin (AMEX:CYBN) shares closed down 6.25% at $1.05 ATAI...

Via Benzinga

Allied, Cybin Among Top Psychedelic Movers Of Today ↗

February 10, 2022

GAINERS: Allied (OTC:ALID) shares closed up 7.39% at $1.89

Via Benzinga

Psychedelic Stock Gainers And Losers From February 9, 2022 ↗

February 09, 2022

GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 14.29% at $5.76

Via Benzinga

Cathie Wood Is Buying this Peter Thiel-Backed Psychedelics Stock For Ark Funds ↗

February 09, 2022

There’s a new psychedelics company being added to an ETF from Cathie Wood. What Happened: The Ark Genomic Revolution ETF (BATS: ARKG) took an initial position in shares of...

Via Benzinga

Mindset Pharma, Cybin Among Top Psychedelic Movers Of Today ↗

February 08, 2022

GAINERS: Awakn Life Sciences (OTC:AWKNF) shares closed up 3.51% at $1.62

Via Benzinga

Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today ↗

February 07, 2022

GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 9.82% at $1.23

Via Benzinga

Is The Psychedelics Sector In Decline? This $30M VC Fund Says HOLD ↗

February 07, 2022

This article was originally published on Microdose and appears here with permission. Recently, there has been an exciting discussion in LinkedIn posts and Microdose PsyCap events regarding the presumed...

Via Benzinga

Small Pharma, Mind Medicine Among Top Psychedelic Movers Of Today ↗

February 04, 2022

GAINERS: Small Pharma (OTC:DMTTF) shares closed up 7.29% at $0.20

Via Benzinga

Field Trip Health, Seelos Therapeutics Among Top Psychedelic Movers Of Today ↗

February 03, 2022

GAINERS: Small Pharma (OTC:DMTTF) shares closed up 6.29% at $0.19

Via Benzinga

< Previous 1 2

...

27 28 29 30 31 32 33 34 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.